Federal Health Minister Mark Butler orders a parliamentary inquiry into online clinics and related services that prescribe or sell peptide drugs, following growing health and safety concerns.

Multiple outlets say the investigation focuses on telehealth operators and social media platforms associated with the promotion of peptides described as “wonder-drug” products, and the inquiry aims to assess how these substances are being prescribed and sold. The reporting reflects concern about unapproved drug use facilitated through online channels.

Across the coverage, outlets generally agree on the existence of the federal inquiry and the key actors it targets—online prescribing practices, telehealth providers, and the platforms that help drive demand. One publication also highlights that at least one person in Australia has experienced severe consequences, including a near-fatal outcome, as part of the rationale for action. Other outlets primarily emphasize the minister’s directive and the scale of the “boom” in online peptide prescribing without adding further incident detail.